Form 4: Precigen Director Fred Hassan Boosts Equity Stake

Precigen Director Fred Hassan received common stock, restricted stock units, and stock options as part of his annual compensation package, aligning his interests with shareholders.

Summary

• Director Fred Hassan acquired 17,948 shares of Precigen Common Stock at $3.51 per share, issued in lieu of a $63,000 annual retainer.
• He also received 35,612 Restricted Stock Units (RSUs), each representing a contingent right to one share of Precigen common stock, which will vest in full on March 10, 2027.
• Additionally, Hassan was granted 41,073 options to purchase common stock with an exercise price of $3.51, exercisable from March 10, 2026, and expiring on March 10, 2036.
• Following these transactions, Fred Hassan beneficially owns 1,171,400 shares of common stock, 35,612 Restricted Stock Units, and 41,073 options to purchase common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates continued alignment of a director's interests with the company's performance through equity compensation, which is a standard and healthy corporate governance practice.

Positives

• Director Fred Hassan's acquisition of equity awards aligns his financial interests with those of Precigen shareholders, promoting long-term value creation.
• The issuance of common stock in lieu of a cash retainer demonstrates a commitment to equity-based compensation, further tying the director's incentives to company performance.

Negatives

• The equity awards are part of compensation and not a direct cash investment by the director, which some investors might view differently than an open market purchase.

Future Outlook

The Restricted Stock Units are scheduled to vest in full on March 10, 2027, and the stock options are exercisable from March 10, 2026, until their expiration on March 10, 2036.

Industry Context

StockSavvy.ai notes that providing equity-based compensation to directors is a standard practice across industries, designed to align the interests of board members with long-term shareholder value. This type of compensation is common for publicly traded biotechnology and pharmaceutical companies like Precigen, Inc.

Comparison to Industry Standards

• Director compensation packages in the biotechnology sector, similar to those at companies like Moderna or BioNTech, frequently include a mix of cash retainers and equity awards such as restricted stock units and stock options.
• This structure aims to incentivize long-term performance and strategic oversight. The equity awards granted to Fred Hassan are consistent with typical compensation structures for non-executive directors in comparable life sciences companies.

Related Party Transactions

• The acquisition of common stock, restricted stock units, and stock options by Director Fred Hassan constitutes a related party transaction as it involves compensation from the issuer to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial incentives with the company's stock performance, potentially benefiting shareholders through improved governance and strategic decisions.
• Employees: No direct impact on employees is indicated by this filing.
• Customers: No direct impact on customers is indicated by this filing.
• Suppliers: No direct impact on suppliers is indicated by this filing.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Vesting of 35,612 Restricted Stock Units on March 10, 2027.
• Potential exercise of 41,073 stock options by March 10, 2036.

Key Dates

Recommendation

This Form 4 details routine director compensation through equity awards, which is a standard practice for aligning management and board interests with shareholders. It does not present new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in an existing investment thesis. Therefore, a 'hold' recommendation is appropriate as the filing confirms standard corporate governance without providing catalysts for a 'buy' or 'sell'.

Keywords

Precigen, PGEN, Fred Hassan, Director Compensation, Insider Transaction, Form 4, Equity Awards, Restricted Stock Units, Stock Options, Corporate Governance